Communiqués Johnson & Johnson Xetra

Actions

JNJ

US4781601046

Marché Fermé - Xetra Autres places de cotation 17:35:46 03/07/2024			Après clotûre 18:34:30
134,4 ^EUR	-1,50%		134,6	+0,17%

16:30	Santé Canada approuve le Rybrevant de Johnson & Johnson pour le traitement du cancer du poumon avancé	MT
12:07	J&J : approbation complète pour Sirturo dans la tuberculose	CF

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	14:01	AQ
State AG Updates: June 6-13, 2024	02/07	AQ
CHMP adopts positive opinion for BALVERSA for the treatment of adult patients	01/07	AQ
Johnson & Johnson - Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class	01/07	AQ
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	28/06	PU
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	28/06	PR
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	28/06	PU
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	28/06	BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	27/06	AQ
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06	AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.	24/06	AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	21/06	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	21/06	AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	20/06	PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	20/06	BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	20/06	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	18/06	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	17/06	BU
J&J commits five-year investment in Italian medicine manufacturing	17/06	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	17/06	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30